About Us

We are Proteon Pharmaceuticals

Proteon Pharmaceuticals modulates the microbiome to improve animal and human health. Our products allow farmers to reduce the need to use antibiotics, enable more sustainable agriculture, improve food safety/quality and increase productivity by eliminating on-farm animal health challenges.

Choose Us

Dedicated to Bacteriophage Research & Application For Almost 15 Years

Proteon Pharmaceuticals is devoted to improving your productivity and contributing to environmental sustainability goals by providing the best feed additives for animal health.
Our knowledge, expertise, and technology is at your service.

  • Our highly skilled and experienced team works single-mindedly to provide you with innovative new tools.
  • Proteon Pharmaceuticals uses precision biology and the latest tools in the market to provide you with the best solutions.
  • We join our hands with you, no matter where you are in your production cycle and use our expertise to help you meet your goals.
  • Our products eliminate the unnecessary use of antibiotics, improve the quality of production & are eco-friendly.

Navigating the Future

Our Mission and Vision

Proteon Pharmaceuticals uses precision biology to modulate the microbiome to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

We deliver natural, safe and environmentally sustainable products developed from our patented phage-platform technology.

Proteon Pharmaceuticals partners with farmers to provide solutions that improve the economic efficiency of farms, while promoting environmentally sound, natural and sustainable solutions.

Team Spotlight

Meet Our Dedicated Management Team

Prof. Jarosław Dastych, PhD
Founder & Chief Executive Officer

Prof. Jarosław Dastych

Founder & Chief Executive Officer

Prof. Jarosław Dastych is the Founder, CEO, and Board President of Proteon Pharmaceuticals S.A., a leading biotech company and a global leader in bacteriophage technology for livestock farming and aquaculture. His research interests range from immunology, toxicology and molecular biology to the development of novel diagnostic tools and bacteriophage-based or related treatment of disease.

After being awarded his PhD in Medical Biology from the Medical University of Łódź in 1991, Prof. Dastych furthered his career with significant contributions at different research institution in Poland and USA, including National Institutes of Health in Bethesda, International Institute of Molecular and Cell Biology in Warsaw, and Institute of Medical Biology of the Polish Academy of Sciences in Lodz.

In 2005 prof. Dastych channelled his passion for bacteriophages into the creation of Proteon Pharmaceuticals, leading to the development of a unique bacteriophage platform technology. This innovation offers sustainable solutions to bacterial disease management in animal farming, aquaculture, as well as egg and poultry production, earning international recognition and various innovation awards.

Prof. Dastych’s leadership extends beyond corporate boundaries, having overseen twelve European R&D projects. Furthermore, his scholarly contributions include over 70 papers in esteemed scientific journals and co-authorship of 12 biotechnology-related patents, underscoring his diverse expertise and commitment to scientific advancement.

Justyna Andrysiak
Chief Product & Technology Officer

Justyna Andrysiak

Chief Product & Technology Officer

Justyna Andrysiak, Chief Product & Technology Officer, combines a passion for biotechnology and a keen grasp of the transformative power of phage technology. Having been part of the Proteon team since 2009, her vital contributions to phage-based solutions have helped bridge the gap between scientific research and practical applications.

In her role, Justyna continually fosters innovation and partnerships, driving both Proteon and the broader field of biotechnology and phage technology forward. Her leadership skills have been honed over years of managing complex phage-related projects and leading diverse cross-functional teams.

Justyna has successfully acquired over EUR 7.7mln in non-dilutive R&D and commercial grants. Navigating the dynamic biotech landscape, she has harnessed emerging trends and breakthroughs, successfully overseeing the development and management of various biotech products. Justyna’s collaborative approach and strong leadership have ensured the smooth transition of projects from conception to commercialization, significantly advancing the practical application of phage-based products.

Committed to the future of phage technology, Justyna’s focus is on pioneering advancements that promote sustainable farming, contributing to a better, more sustainable future.

Márcio Caparroz
Chief
Commercial Officer

Márcio Caparroz
Chief Commercial Officer

Márcio Caparroz is the Chief Commercial Officer (CCO) at Proteon Pharmaceuticals S.A., where he is responsible for shaping and implementing a commercial strategy that resonates with the company’s vision and mission. His responsibilities extend to establishing and leading commercial teams, including managing distributor relationships and facilitating cross- functional coordination in licensing and additional agreements.

Márcio has over 20 years of international experience with multinational companies in Animal Nutrition and Health, focusing on meeting customers’ unmet needs. He has a proven track record of delivering significant results by identifying market opportunities in complex scenarios. Márcio’s collaborative leadership style enhances the strengths of individual team members, motivating them to achieve exceptional results. He combines strong analytical abilities with a creative approach, pragmatically driving business revenue growth through innovation and strategic insight.

His main accomplishments include the commercial management, engagement, and development of service strategies for global key accounts such as JBS/Pilgrims, Tyson, Agrosuper, and McDonald’s, among others. He revamped the Go-to-Market strategy across various animal sectors, achieving over 50% year-over-year sales growth in the last three years. Additionally, Márcio led the customization of the Global Portfolio, tailoring products and services to regional needs and driving innovation in tackling challenges like Salmonella and E.coli, demonstrating a strong capacity for leadership and strategic development.

Jakub Korczak
Chief
Financial Officer

Jakub Korczak

Chief Financial Officer

Jakub is the Chief Financial Officer of Proteon Pharmaceuticals, overseeing comprehensive financial management and reporting, budgeting, long-term planning, and leading the company’s fundraising and capital markets initiatives. With over 25 years of professional experience, he has held CFO and board member roles in both public and private companies across Europe and North America.

Jakub excels in managing capital markets activities, including conducting IPOs/SPOs, securing funding through equity and debt, and executing extensive M&A projects. Jakub holds a degree in Financial Management and Accounting from the University of Lodz (Poland) and he has further enhanced his expertise through the Advanced Management Program at IESE Business School in Barcelona (Spain).

Bruno Maineult
Chief Transformation & Strategy Officer

Bruno Maineult

Chief Transformation & Strategy Officer

Bruno Maineult is the Chief Transformation & Strategy Officer of Proteon Pharmaceuticals SA, as well as the Chief Executive Officer of its AI subsidiary, PhageAI SA. He has over 20 years of experience in management in Poland and Europe including his roles as Board Member of a German tech corporation controlled by Private Equity and Head of Financial Planning & Analysis of the Polish telecom incumbent.

Cross-cultural fluent and a Hi-tech enthusiast, Bruno has developed a solid experience in Biotech for the last 7 years now.

Beyond his work experience in companies of all sizes, he has built his entrepreneurial skills through participating in several innovative projects in education, multimedia and financial services as a Freelancer and as an Angel Investor in Poland.

Bruno is savvy about organization management and the impact of digitalization on individual and collective performance, including the strengthening of effective and synergetic cooperation between teams.

Małgorzata Stańczyk, PhD
Chief Registration &
IP Officer

Małgorzata Stańczyk, PhD
Chief Registration & IP Officer

Małgorzata is the Chief Registration and IP Officer at Proteon Pharmaceuticals where she is responsible for providing regulatory support and guidance to project teams, preparing and submitting the registration dossiers for approval in across Asia, both Americas, and the EU. From devising regulatory strategies to ensuring final approvals, Małgorzata adeptly manages the entire registration process. Beyond registration, she takes the helm on intellectual property matters, encompassing patents and trademarks, and diligently oversees the company’s IP strategy.

Holding a PhD in Biochemistry from the University of Łódź, Małgorzata further enriched her academic credentials in 2014 by completing postgraduate studies in “Management of Research Projects” from Gdynia Maritime University and the Centre for Consultancy and Training. She is a co-author of over 29 publications in scientific journals in the field of cytotoxicity and molecular biology.

Ewelina Wójcik, PhD
Chief
Scientific Officer

Ewelina Wójcik, PhD

ChiefScientific Officer

Ewelina is the Chief Scientific Officer at Proteon Pharmaceuticals where she manages a +50-person R&D Function. A scientist in the fields of Microbiology and Molecular Genetics, wrote her Ph.D. thesis on “Unusual DNA structures as endogenous mutagens in mycobacteria”. She is responsible for the scientific development of bacteriophage products (BAFASAL®, BAFADOR®, BAFACOL®, BAFACAM®).

She is a co-author of 12 publications in scientific journals and over 30 patent applications.

Arkadiusz Wojtasik, PhD
Chief Manufacturing Officer

Arkadiusz Wojtasik, PhD
Chief Manufacturing Officer

As Chief Manufacturing Officer, Arkadiusz is responsible for the production of innovative and effective phage products, optimization of bioprocess and scale-up operations. Proficient, dedicated and quality-oriented manager who supervises a skilled team of biotechnologists and specialists, supporting a dynamic, innovative and positive work environment. Co-Developer of several novel products and the related exclusive know-how in Proteon Pharmaceuticals. As scientist in the fields of biotechnology, microbiology & genetics, he successfully built up a first manufacturing line from the scratch using breakthrough proprietary technology. In addition, Arkadiusz is still developing of production area by formation of new facilities and technology transfer.

Jarosław Dastych, PhD

Founder & Chief Executive Officer

Prof. Jarosław Dastych is the Founder, CEO, and Board President of Proteon Pharmaceuticals S.A., a leading biotech company and a global leader in bacteriophage technology for livestock farming and aquaculture. His research interests range from immunology, toxicology and molecular biology to the development of novel diagnostic tools and bacteriophage-based or related treatment of disease.

After being awarded his PhD in Medical Biology from the Medical University of Łódź in 1991, Prof. Dastych furthered his career with significant contributions at different research institution in Poland and USA, including National Institutes of Health in Bethesda, International Institute of Molecular and Cell Biology in Warsaw, and Institute of Medical Biology of the Polish Academy of Sciences in Lodz.

In 2005 prof. Dastych channelled his passion for bacteriophages into the creation of Proteon Pharmaceuticals, leading to the development of a unique bacteriophage platform technology. This innovation offers sustainable solutions to bacterial disease management in animal farming, aquaculture, as well as egg and poultry production, earning international recognition and various innovation awards.

Prof. Dastych’s leadership extends beyond corporate boundaries, having overseen twelve European R&D projects. Furthermore, his scholarly contributions include over 70 papers in esteemed scientific journals and co-authorship of 12 biotechnology-related patents, underscoring his diverse expertise and commitment to scientific advancement.

Justyna Andrysiak

Chief Product & Technology Officer

Justyna Andrysiak, Chief Product & Technology Officer, combines a passion for biotechnology and a keen grasp of the transformative power of phage technology. Having been part of the Proteon team since 2009, her vital contributions to phage-based solutions have helped bridge the gap between scientific research and practical applications.

In her role, Justyna continually fosters innovation and partnerships, driving both Proteon and the broader field of biotechnology and phage technology forward. Her leadership skills have been honed over years of managing complex phage-related projects and leading diverse cross-functional teams.

Justyna has successfully acquired over EUR 7.7mln in non-dilutive R&D and commercial grants. Navigating the dynamic biotech landscape, she has harnessed emerging trends and breakthroughs, successfully overseeing the development and management of various biotech products. Justyna’s collaborative approach and strong leadership have ensured the smooth transition of projects from conception to commercialization, significantly advancing the practical application of phage-based products.

Committed to the future of phage technology, Justyna’s focus is on pioneering advancements that promote sustainable farming, contributing to a better, more sustainable future.

Márcio Caparroz

Chief Commercial Officer

Márcio Caparroz is the Chief Commercial Officer (CCO) at Proteon Pharmaceuticals S.A., where he is responsible for shaping and implementing a commercial strategy that resonates with the company’s vision and mission. His responsibilities extend to establishing and leading commercial teams, including managing distributor relationships and facilitating cross- functional coordination in licensing and additional agreements.

Márcio has over 20 years of international experience with multinational companies in Animal Nutrition and Health, focusing on meeting customers’ unmet needs. He has a proven track record of delivering significant results by identifying market opportunities in complex scenarios. Márcio’s collaborative leadership style enhances the strengths of individual team members, motivating them to achieve exceptional results. He combines strong analytical abilities with a creative approach, pragmatically driving business revenue growth through innovation and strategic insight.

His main accomplishments include the commercial management, engagement, and development of service strategies for global key accounts such as JBS/Pilgrims, Tyson, Agrosuper, and McDonald’s, among others. He revamped the Go-to-Market strategy across various animal sectors, achieving over 50% year-over-year sales growth in the last three years. Additionally, Márcio led the customization of the Global Portfolio, tailoring products and services to regional needs and driving innovation in tackling challenges like Salmonella and E.coli, demonstrating a strong capacity for leadership and strategic development.

Jakub Korczak

Chief Financial Officer

Jakub is the Chief Financial Officer of Proteon Pharmaceuticals, overseeing comprehensive financial management and reporting, budgeting, long-term planning, and leading the company’s fundraising and capital markets initiatives. With over 25 years of professional experience, he has held CFO and board member roles in both public and private companies across Europe and North America.

Jakub excels in managing capital markets activities, including conducting IPOs/SPOs, securing funding through equity and debt, and executing extensive M&A projects. Jakub holds a degree in Financial Management and Accounting from the University of Lodz (Poland) and he has further enhanced his expertise through the Advanced Management Program at IESE Business School in Barcelona (Spain).

Bruno Maineult

Chief People & AI Officer

Bruno Maineult is the Chief People & AI Officer of Proteon Pharmaceuticals SA, as well as the Chief Executive Officer of its AI subsidiary, PhageAI SA. He has over 20 years of experience in management in Poland and Europe including his roles as Board Member of a German tech corporation controlled by Private Equity and Head of Financial Planning & Analysis of the Polish telecom incumbent.

Cross-cultural fluent and a Hi-tech enthusiast, Bruno has developed a solid experience in Biotech for the last 7 years now.

Beyond his work experience in companies of all sizes, he has built his entrepreneurial skills through participating in several innovative projects in education, multimedia and financial services as a Freelancer and as an Angel Investor in Poland.

Bruno is savvy about organization management and the impact of digitalization on individual and collective performance, including the strengthening of effective and synergetic cooperation between teams.

Małgorzata Stańczyk, PhD

Chief Registration & IP Officer

Małgorzata is the Chief Registration and IP Officer at Proteon Pharmaceuticals where she is responsible for providing regulatory support and guidance to project teams, preparing and submitting the registration dossiers for approval in across Asia, both Americas, and the EU. From devising regulatory strategies to ensuring final approvals, Małgorzata adeptly manages the entire registration process. Beyond registration, she takes the helm on intellectual property matters, encompassing patents and trademarks, and diligently oversees the company’s IP strategy.

Holding a PhD in Biochemistry from the University of Łódź, Małgorzata further enriched her academic credentials in 2014 by completing postgraduate studies in “Management of Research Projects” from Gdynia Maritime University and the Centre for Consultancy and Training. She is a co-author of over 29 publications in scientific journals in the field of cytotoxicity and molecular biology.

Ewelina Wójcik, PhD

Chief Scientific Officer

Ewelina is the Chief Scientific Officer at Proteon Pharmaceuticals where she manages a +50-person R&D Function. A scientist in the fields of Microbiology and Molecular Genetics, wrote her Ph.D. thesis on “Unusual DNA structures as endogenous mutagens in mycobacteria”. She is responsible for the scientific development of bacteriophage products (BAFASAL®, BAFADOR®, BAFACOL®, BAFACAM®).

She is a co-author of 12 publications in scientific journals and over 30 patent applications.

Arkadiusz Wojtasik, PhD

Chief Manufacturing Officer

Bruno Maineult is the Chief Transformation & Strategy Officer of Proteon Pharmaceuticals SA, as well as the Chief Executive Officer of its AI subsidiary, PhageAI SA. He has over 20 years of experience in management in Poland and Europe including his roles as Board Member of a German tech corporation controlled by Private Equity and Head of Financial Planning & Analysis of the Polish telecom incumbent.

Cross-cultural fluent and a Hi-tech enthusiast, Bruno has developed a solid experience in Biotech for the last 7 years now.

Beyond his work experience in companies of all sizes, he has built his entrepreneurial skills through participating in several innovative projects in education, multimedia and financial services as a Freelancer and as an Angel Investor in Poland.

Bruno is savvy about organization management and the impact of digitalization on individual and collective performance, including the strengthening of effective and synergetic cooperation between teams.

Prof. Jaroslaw Dastych, PhD
Founder & Chief Executive Officer

Professor Jaroslaw Dastych is the Founder, CEO and President of the…
READ MORE

Prof. Jarosław Dastych

Founder & Chief Executive Officer

Prof. Jarosław Dastych is the Founder, CEO, and Board President of Proteon Pharmaceuticals S.A., a leading biotech company and a global leader in bacteriophage technology for livestock farming and aquaculture. His research interests range from immunology, toxicology and molecular biology to the development of novel diagnostic tools and bacteriophage-based or related treatment of disease.

After being awarded his PhD in Medical Biology from the Medical University of Łódź in 1991, Prof. Dastych furthered his career with significant contributions at different research institution in Poland and USA, including National Institutes of Health in Bethesda, International Institute of Molecular and Cell Biology in Warsaw, and Institute of Medical Biology of the Polish Academy of Sciences in Lodz.

In 2005 prof. Dastych channelled his passion for bacteriophages into the creation of Proteon Pharmaceuticals, leading to the development of a unique bacteriophage platform technology. This innovation offers sustainable solutions to bacterial disease management in animal farming, aquaculture, as well as egg and poultry production, earning international recognition and various innovation awards.

Prof. Dastych’s leadership extends beyond corporate boundaries, having overseen twelve European R&D projects. Furthermore, his scholarly contributions include over 70 papers in esteemed scientific journals and co-authorship of 12 biotechnology-related patents, underscoring his diverse expertise and commitment to scientific advancement.

Bruno Maineult
Chief Transformation & Strategy Officer

Bruno Maineult is the Chief Transformation & Strategy Officer of Proteon Pharmaceuticals SA…

READ MORE

Bruno Maineult

Chief Transformation & Strategy Officer

Bruno Maineult is the Chief Transformation & Strategy Officer of Proteon Pharmaceuticals SA, as well as the Chief Executive Officer of its AI subsidiary, PhageAI SA. He has over 20 years of experience in management in Poland and Europe including his roles as Board Member of a German tech corporation controlled by Private Equity and Head of Financial Planning & Analysis of the Polish telecom incumbent.

Cross-cultural fluent and a Hi-tech enthusiast, Bruno has developed a solid experience in Biotech for the last 7 years now.

Beyond his work experience in companies of all sizes, he has built his entrepreneurial skills through participating in several innovative projects in education, multimedia and financial services as a Freelancer and as an Angel Investor in Poland.

Bruno is savvy about organization management and the impact of digitalization on individual and collective performance, including the strengthening of effective and synergetic cooperation between teams.

Where Do We Operate

Join Hands With Us! Find Us Here
Headquarters & Legal Address:
UI. Tylna 3a 90-364 Lodz, Poland
Commercial Office Address
LIM Center 18th Floor AI. Jerfozolimskie 65/79, 00-697 Warsaw, poland
Asia Office Address
VETPHAGE PHARMACEUTICALS PRIVATE LIMITED A-310, Western Edge II, Behind Metro Mall,Western Express Highway, Borivali East, Mumbai, Maharashtra, India. 400 066

Discover

Our story: Watch Our Video